Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

NCT07537088 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

468

Enrollment

OTHER

Sponsor class

Conditions

T2DM (Type 2 Diabetes Mellitus)
CKD - Chronic Kidney Disease

Interventions

DRUG: Dulaglutide
DRUG: SGLT2i
DRUG: Finerenone

Sponsor

First Affiliated Hospital of Wannan Medical College